SIRT1 and fatty liver disease: In addition, inhibition of PARP-1 can also increase NAD+ content and SIRT1 activity, enhance lipid metabolism, and improve hepatic steatosis in mice fed a high-fat diet (Kraus and Hottiger, 2013).